bioavailability is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-12. Numbers and descriptions here follow the published literature rather than marketing material.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
"Layne was really responsible for giving me the confidence to become more of a singer. He'd say, 'You wrote this song, this means something to you, sing it.' He kicked my ass out of the nest. Over the years I continued to grow, and Layne started to play guitar, and we inspired each other". Since 2002, Seattle has hosted an annual tribute concert for Staley on his birthday. Venues such as the Moore Theatre, The Showbox The Fenix, and The Crocodile have hosted the event. The show proceeds benefit the Layne Staley Memorial Fund. Staley ranked at No. 27 on Hit Parader magazine's list of "Heavy Metal's All-Time Top 100 Vocalists" published in the November 2006 issue, and at No. 42 on Complex's magazine list of "The 50 Best Lead Singers of All Time" in 2012. Staley was an inspiration for the title of Metallica's 2008 album, Death Magnetic. The band recorded a song in tribute to him, titled "Rebel of Babylon". In 2009, Alice in Chains released their first studio album in 14 years, Black Gives Way to Blue, with Cantrell and then-new vocalist and rhythm guitarist William DuVall sharing lead vocals. The title track is a tribute to Staley. Cantrell invited Elton John to join Alice in Chains and pay tribute to Staley playing the piano in "Black Gives Way to Blue", the closing song in the album. The song was written and sung by Cantrell, who described it as the band's goodbye to Staley. The first concert that Staley attended was Elton John's and he was blown away by it.
While working at St Mary's Hospital, London, in 1928, a Scottish physician, Alexander Fleming, was investigating the pattern of variation in S. aureus. He was inspired by the discovery of an Irish physician, Joseph Warwick Bigger, and his two students, C.R. Boland and R.A.Q. O’Meara, at Trinity College, Dublin, in 1927. Bigger and his students found that when they cultured a particular strain of S. aureus, which they had designated "Y" and isolated a year earlier from the pus of a patient's axillary abscess, the bacterium grew into a variety of strains. They published their discovery as "Variant colonies of Staphylococcus aureus" in The Journal of Pathology and Bacteriology, concluding:
=== Relationships and family === In December 2001, Newsom married legal commentator Kimberly Guilfoyle at Saint Ignatius Catholic Church. They separated in 2004 and jointly filed for divorce in January 2005, citing "difficulties due to their careers on opposite coasts". Their divorce was finalized on February 28, 2006, by which time Guilfoyle was expecting a child with Eric Villency. Guilfoyle gained prominence in 2011 via a Fox News chat show. She was later named senior advisor to Republican president Donald Trump, whom Newsom has extensively criticized, and was later engaged to Donald Trump Jr. In September 2006, Newsom, then 38, briefly dated 19-year-old Brittanie Mountz, a model and restaurant hostess. On January 31, 2007, Newsom's close friend, campaign manager, and former chief of staff Alex Tourk confronted him after learning from his wife, Ruby Rippey-Tourk, that she and Newsom had an affair in 2005, when she was Newsom's appointments secretary. Tourk immediately resigned. Newsom admitted to the affair the next day and apologized to the public, saying he was "deeply sorry" for his "personal lapse of judgment". In 2018, Rippey-Tourk said that she thought it wrong to associate Newsom's behavior with the #MeToo movement: "I was a subordinate, but I was also a free-thinking, 33-yr old adult married woman and mother. I do want to make sure that the #metoo movement is reserved for cases and situations that deserve it." Newsom began dating film director Jennifer Siebel in October 2006. He announced he would seek treatment for alcohol use disorder in February 2007.
Sources: en.wikipedia.org
affected relative pair Any pair of organisms which are related genetically and both affected by the same trait. For example, two cousins who both have blue eyes are an affected relative pair since they are both affected by the allele that codes for blue eyes.
While the fair was profitable, it nevertheless left Knoxville in debt, and failed to spark the redevelopment boom Testerman, Tyree, and the fair's promoters had envisioned. Furthermore, on the day after the fair closed, the FDIC raided all of Butcher's banks, leading to the collapse of his banking empire, and threatening the city's financial stability. Testerman replaced an embattled Tyree as mayor in 1983, and attempted to reinvigorate interest in his downtown redevelopment plans.
Abdomen and rectum Cardiovascular (heart and blood vessels) General appearance of the patient and specific indicators of disease (nutritional status, presence of jaundice, pallor or clubbing) Genitalia (and pregnancy if the patient is or could be pregnant) Head, eye, ear, nose, and throat (HEENT) Musculoskeletal (including spine and extremities) Neurological (consciousness, awareness, brain, vision, cranial nerves, spinal cord and peripheral nerves) Psychiatric (orientation, mental state, mood, evidence of abnormal perception or thought). Respiratory (large airways and lungs) Skin Vital signs including height, weight, body temperature, blood pressure, pulse, respiration rate, and hemoglobin oxygen saturation It is to likely focus on areas of interest highlighted in the medical history and may not include everything listed above. The treatment plan may include ordering additional medical laboratory tests and medical imaging studies, starting therapy, referral to a specialist, or watchful observation. A follow-up may be advised. Depending upon the health insurance plan and the managed care system, various forms of "utilization review", such as prior authorization of tests, may place barriers on accessing expensive services. The medical decision-making (MDM) process includes the analysis and synthesis of all the above data to come up with a list of possible diagnoses (the differential diagnoses), along with an idea of what needs to be done to obtain a definitive diagnosis that would explain the patient's problem.
Scutellaria is a genus of flowering plants in the mint family, Lamiaceae. They are known commonly as skullcaps. The generic name is derived from the Latin scutella, meaning "a small dish, tray or platter", or "little dish", referring to the shape of the calyx. The common name alludes to the resemblance of the same structure to "miniature medieval helmets". The genus has a subcosmopolitan distribution, with species occurring nearly worldwide, mainly in temperate regions.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.